ruxolitinib (Jakavi)


( Last Updated : July 12, 2021)
Generic Name:
ruxolitinib
Project Status:
Pending
Therapeutic Area:
Graft versus host disease
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Jakavi
Project Line:
Reimbursement Review
Project Number:
SR0688-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Jakavi is indicated for the treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Jakavi is indicated for the treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.